Iovance Raises 2025 Revenue Outlook to $250–300M, Lifileucel Lung Cancer Potential 7× Larger
Iovance Biotherapeutics expects first full calendar year Amtagvi sales to deliver $250–300 million in 2025 revenue and forecasts up to $1 billion in peak sales potential for the advanced melanoma treatment. The company projects Lifileucel’s lung cancer commercial opportunity to be up to seven times larger than its melanoma market and holds $307 million cash runway through Q2 2027.
1. Revenue Guidance Update
Iovance Biotherapeutics forecasts first full-year 2025 revenues of $250 million to $300 million driven by Amtagvi sales, aligning with its previously disclosed guidance range. This update reflects the company’s confidence in early market adoption of its advanced melanoma cell therapy.
2. Amtagvi Peak Sales Potential
The company estimates Amtagvi could achieve up to $1 billion in peak annual sales as a treatment regimen for advanced melanoma. This projection underscores Iovance’s expectations for broad patient uptake and pricing power in the melanoma therapy market.
3. Lifileucel Lung Cancer Opportunity
Lifileucel, Iovance’s in-development lung cancer cell therapy, is anticipated to complete enrollment and data updates this year, with a projected launch in the second half of 2027. Iovance believes the lung cancer market for Lifileucel could be up to seven times larger than its current opportunity in melanoma.
4. Cash Runway and Financial Position
Iovance reported $307 million in cash and cash equivalents, sufficient to fund operations through the second quarter of 2027. This cash position supports ongoing clinical development and commercial preparations for both Amtagvi and Lifileucel.